Emodin’s well‑documented inhibition of EGFR/MAPK signaling reduces inflammation in kidney injury models [3] and interferes with EGFR/Ras expression to maintain inflammatory homeostasis [3]. If aging is an evolutionarily preserved program that employs EGFR activity to enforce post‑reproductive senescence and resource clearance for kin [1][2], then emodin may not merely suppress inflammation but directly attenuate a conserved aging module. We hypothesize that emodin extends healthspan by dampening an EGFR‑driven senescence program rather than by indiscriminate senolysis, thereby negotiating with the evolved mechanism instead of overriding it.

Mechanistic rationale: EGFR signaling activates downstream MAPK and NF‑κB pathways that promote a pro‑inflammatory SASP in senescent cells [4]. In many organisms, EGFR activity rises after reproductive age, aligning with the timing of programmed aging signals [2]. By blocking EGFR autophosphorylation and Ras activation, emodin could lower the transcriptional output of SASP components (IL‑6, IL‑1β, TNF‑α) without triggering apoptosis, thus preserving tissue homeostasis while reducing the deleterious signaling that drives age‑related pathology. This differs from classic senolytics that kill senescent cells; emodin would reprogram the secretome, converting a deleterious SASP to a benign or even beneficial profile.

Testable predictions:

1. In wild‑type mice, chronic low‑dose emodin treatment will delay onset of age‑related phenotypes (frailty, glucose intolerance) and extend median lifespan relative to vehicle controls.
2. The lifespan extension will be absent in mice with liver‑specific EGFR knockout, indicating dependence on EGFR signaling.
3. Emodin‑treated old mice will show reduced EGFR phosphorylation and downstream ERK/Akt activity in spleen and liver, accompanied by decreased SASP cytokine levels in plasma, but unchanged senescent cell burden as measured by p16^INK4a^ or SA‑β‑gal staining.
4. Ex vivo culture of human senescent fibroblasts exposed to emodin will exhibit lowered IL‑6 and IL‑1β secretion without increased apoptosis (caspase‑3/7 activity), confirming a secretome‑shifting effect.
5. Transcriptomic analysis will reveal enrichment of EGFR‑downstream gene sets being reversed, while pathways unrelated to EGFR (e.g., mTOR autophagy) remain unchanged.

Falsifiable outcomes: If emodin fails to improve longevity in wild‑type mice, or if its benefits persist despite EGFR loss, the hypothesis that it acts via an EGFR‑dependent aging program is weakened. Likewise, if emodin’s primary effect is senocyte clearance rather than secretome modulation, the predicted dissociation between SASP reduction and senescent cell load would not hold.

By framing emodin as a modulator of an evolutionarily maintained EGFR‑driven aging signal, this hypothesis bridges anti‑inflammatory pharmacology with programmed aging theory, offering a testable avenue for longevity interventions that work with rather than against evolved biology.